ARCT
Price
$7.33
Change
+$0.01 (+0.14%)
Updated
Feb 4 closing price
Capitalization
208.28M
25 days until earnings call
Intraday BUY SELL Signals
QNCX
Price
$0.16
Change
+$0.01 (+6.67%)
Updated
Feb 4 closing price
Capitalization
8.85M
26 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARCT vs QNCX

Header iconARCT vs QNCX Comparison
Open Charts ARCT vs QNCXBanner chart's image
Arcturus Therapeutics Holdings
Price$7.33
Change+$0.01 (+0.14%)
Volume$496.13K
Capitalization208.28M
Quince Therapeutics
Price$0.16
Change+$0.01 (+6.67%)
Volume$5.15M
Capitalization8.85M
ARCT vs QNCX Comparison Chart in %
ARCT
Daily Signal:
Gain/Loss:
QNCX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ARCT vs. QNCX commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and QNCX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (ARCT: $7.33 vs. QNCX: $0.16)
Brand notoriety: ARCT and QNCX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 82% vs. QNCX: 189%
Market capitalization -- ARCT: $208.28M vs. QNCX: $8.85M
ARCT [@Biotechnology] is valued at $208.28M. QNCX’s [@Biotechnology] market capitalization is $8.85M. The market cap for tickers in the [@Biotechnology] industry ranges from $119.38B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileQNCX’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • QNCX’s FA Score: 0 green, 5 red.
According to our system of comparison, QNCX is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while QNCX’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 5 bearish.
  • QNCX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than QNCX.

Price Growth

ARCT (@Biotechnology) experienced а -0.54% price change this week, while QNCX (@Biotechnology) price change was -95.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.41%. For the same industry, the average monthly price growth was +1.41%, and the average quarterly price growth was +32.47%.

Reported Earning Dates

ARCT is expected to report earnings on Mar 02, 2026.

QNCX is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (-2.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($208M) has a higher market cap than QNCX($8.85M). ARCT YTD gains are higher at: 19.576 vs. QNCX (-95.257). QNCX has higher annual earnings (EBITDA): -44.18M vs. ARCT (-60.46M). ARCT has more cash in the bank: 180M vs. QNCX (26.3M). QNCX has less debt than ARCT: QNCX (18M) vs ARCT (26M). ARCT has higher revenues than QNCX: ARCT (85.1M) vs QNCX (0).
ARCTQNCXARCT / QNCX
Capitalization208M8.85M2,351%
EBITDA-60.46M-44.18M137%
Gain YTD19.576-95.257-21%
P/E RatioN/AN/A-
Revenue85.1M0-
Total Cash180M26.3M684%
Total Debt26M18M144%
FUNDAMENTALS RATINGS
ARCT vs QNCX: Fundamental Ratings
ARCT
QNCX
OUTLOOK RATING
1..100
7767
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
47
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
6499
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QNCX's Valuation (47) in the Biotechnology industry is in the same range as ARCT (56) in the Pharmaceuticals Major industry. This means that QNCX’s stock grew similarly to ARCT’s over the last 12 months.

QNCX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that QNCX’s stock grew similarly to ARCT’s over the last 12 months.

ARCT's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as QNCX (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to QNCX’s over the last 12 months.

ARCT's Price Growth Rating (64) in the Pharmaceuticals Major industry is somewhat better than the same rating for QNCX (99) in the Biotechnology industry. This means that ARCT’s stock grew somewhat faster than QNCX’s over the last 12 months.

ARCT's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as QNCX (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to QNCX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTQNCX
RSI
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 15 days ago
79%
Bullish Trend 24 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
78%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signal:
Gain/Loss:
QNCX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EVGIF0.360.07
+25.39%
EverGen Infrastructure Corp.
CNSWF1815.00137.75
+8.21%
Constellation Software, Inc.
TRVR52.800.54
+1.04%
Two Rivers Financial Group, Inc.
ALGGF0.12N/A
N/A
Alliance Global Group, Inc.
SGLOF17.82N/A
N/A
FOOD & LIFE COS LTD.

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been closely correlated with VTGN. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if ARCT jumps, then VTGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+0.14%
VTGN - ARCT
79%
Closely correlated
-3.20%
RZLT - ARCT
79%
Closely correlated
-7.62%
MREO - ARCT
78%
Closely correlated
-2.73%
QNCX - ARCT
75%
Closely correlated
+9.28%
LEGN - ARCT
73%
Closely correlated
-0.06%
More

QNCX and

Correlation & Price change

A.I.dvisor indicates that over the last year, QNCX has been closely correlated with MREO. These tickers have moved in lockstep 86% of the time. This A.I.-generated data suggests there is a high statistical probability that if QNCX jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QNCX
1D Price
Change %
QNCX100%
+9.28%
MREO - QNCX
86%
Closely correlated
-2.73%
CALC - QNCX
85%
Closely correlated
+8.37%
TPST - QNCX
84%
Closely correlated
-1.24%
RZLT - QNCX
83%
Closely correlated
-7.62%
GNTA - QNCX
83%
Closely correlated
-1.27%
More